21.09.2016 • Newsconsumer healthcareDede WillamsGSK

Walmsley Named New CEO of GSK

Emma Walmsley has been named to succeed Andrew Witty as CEO of the UK’s...
Emma Walmsley has been named to succeed Andrew Witty as CEO of the UK’s largest drugmaker on his retirement at the end of March 2017.

Emma Walmsley has been named to succeed Andrew Witty as CEO of the UK’s largest drugmaker on his retirement at the end of March 2017. Prior to that, the 47-year-old, who will have the distinction of being the first woman to run a major pharmaceutical company, will join the board of directors from Jan. 1.

GSK’s CEO-designate, who holds an MA in classics and modern languages from Britain’s Oxford University, is married and has four children, joined the drugmaker in 2010 from L’Oreal. In her 17 years with the French consumer cosmetics producer she held a variety of marketing and general management roles in the UK, Europe and USA. From 2007 she was based in Shanghai as general manager, consumer products for L’Oreal China.

Walmsley currently heads GSK’s consumer healthcare business, established as part of the multibillion-dollar 2014 deal in which GSK swapped its cancer-drug unit for Novartis's vaccine business. Some analysts speculate that her selection as CEO may reduce the chances the consumer division will be spun off.

Witty, who had been seen as under pressure from London financial markets to boost profits or break up the company into smaller units, announced his planned retirement in March of this year.  After he leaves the chief executive’s chair, the 52-year old manager who began his career as a GSK trainee and has been CEO since 2008, will take a seat on the board of directors.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.